Targeting Bace2 Protein Shows Promise in Fighting Lipid-dependent Cancers

Researchers at teh Institute of Molecular Oncology (Ifom) in Milan have identified a protein, Bace2, that plays a critical role in the growth of several solid tumors. Their findings suggest that inhibiting Bace2 could offer a novel therapeutic approach for cancers reliant on fat metabolism, including skin and pancreatic cancers.

Bace2 regulates how tumor cells absorb fats. Many cancers exhibit increased fat absorption to fuel their rapid growth and proliferation. By understanding this process, scientists can develop strategies to disrupt it.

The ifom research team discovered that Bace2 is often overexpressed in aggressive tumors. This overexpression directly correlates with increased fat uptake. Blocking Bace2 effectively cuts off this vital nutrient supply, potentially slowing or stopping tumor progression.

This discovery opens new avenues for cancer treatment. Current therapies often focus on directly killing cancer cells, which can have significant side effects. Targeting Bace2 offers a different approach – starving the cancer cells rather than directly attacking them. This could lead to more targeted and less toxic treatments.

Further research is underway to develop specific inhibitors of Bace2. Scientists are optimistic that these inhibitors will demonstrate efficacy in preclinical models and eventually translate into clinical trials for patients with lipid-dependent cancers. The team believes this strategy could be particularly effective when combined with existing cancer therapies.